

| FORM PTO-1449 (REV. 7-80) | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | | | | | | ATTY. DOCKET NO.: 200.1133 | | SERIAL NO.: 09781,884 <i>10/700,906</i> | | | |
|---|----|--|---|---|---|---|---|---|-------------------------------|---|--|----------------|----------------------------|----|
| LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary) | | | | | | | | | | APPLICANT(S): Oshlack, et al. | | | | |
| | | | | | | | | | | FILING DATE: February 8, 2004 <i>11/4/03</i> | | GROUP: 1615 | | |
| U.S. PATENT DOCUMENTS | | | | | | | | | | | | | | |
| *EXAMINER INITIAL | | DOCUMENT NUMBER | | | | | | | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE | |
| HS | AA | 3 | 9 | 6 | 5 | 2 | 5 | 6 | 06/22/1976 | Leslie | 424 | 22 | | |
| | AB | 4 | 2 | 3 | 7 | 1 | 4 | 0 | 12/02/1980 | Dudzinski | 424 | 260 | | |
| | AC | 4 | 3 | 6 | 6 | 3 | 1 | 0 | 12/28/1982 | Leslie | 536 | 56 | | |
| | AD | 4 | 4 | 4 | 3 | 4 | 2 | 8 | 04/17/1984 | Oshlack, et al. | 424 | 22 | | |
| | AE | 4 | 8 | 2 | 8 | 8 | 3 | 6 | 05/09/1989 | Elger, et al. | 424 | 419 | | |
| | AF | 4 | 8 | 3 | 4 | 9 | 6 | 5 | 05/30/1989 | Martani, et al. | 424 | 488 | | |
| | AG | 4 | 8 | 3 | 4 | 9 | 8 | 4 | 05/30/1989 | Goldie, et al. | 424 | 488 | | |
| | AH | 4 | 8 | 3 | 4 | 9 | 8 | 5 | 05/30/1989 | Elger, et al. | 424 | 488 | | |
| ▼ | AI | 4 | 8 | 4 | 4 | 9 | 0 | 7 | 07/04/1989 | Elger, et al. | 424 | 465 | | |
| HS | AJ | 4 | 8 | 4 | 4 | 9 | 0 | 9 | 07/04/1989 | Goldie, et al. | 424 | 480 | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | | | | | | | | |
| | | DOCUMENT NUMBER | | | | | | | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
| | | | | | | | | | | | | | YES | NO |
| HS | AK | 0 | 1 | 9 | 3 | 3 | 5 | 5 | 09/03/1986 | Europe (A3) | A61K | 31/615 | | |
| HS | AL | 0 | 3 | 1 | 9 | 2 | 4 | 3 | 06/07/1989 | Europe (A1) | A61K | 31/485 | | |
| HS | AM | 0 | 3 | 1 | 9 | 2 | 4 | 3 | 11/07/1990 | Europe (A2) | A61K | 31/485 | | |
| HS | AN | 0 | 0 | 0 | 1 | 3 | 7 | 7 | 01/13/2000 | WO | A61K | 31/00 | | |
| HS | AO | 9 | 0 | 0 | 4 | 9 | 6 | 5 | 05/17/1990 | WO | A61K | 31/485 | | |
| OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | | | | | | | | | | |
| HS | AP | Translation of previously submitted German patent application DE 43 25 465 (2003) | | | | | | | | | | | | |
| HS | AQ | Alvarez-Fuentes, et al., "Effectiveness of Repeated Administration of a New Oral Naltrexone Controlled-Release System on Morphine Analgesia"; J. Pharm Pharmacol (2001), 53; pg. 1201-1205 | | | | | | | | | | | | |
| HS | AR | Alvarez-Fuentes, et al., "Preclinical Study of an Oral Controlled Release Naltrexone Complex in Mice"; J. Pharm Pharmacol (2000), 52; pg. 659-663 | | | | | | | | | | | | |
| EXAMINER /Humera Sheikh/ | | | | | | | | | DATE CONSIDERED 01/21/2007 | | | | | |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | | | | | | | | | | |

| | | | | | | | | | | | | | |
|---|----|--|---|---|---|-----------------|---------|---|-------------------------------------|----------------------------|-----|-----|--|
| FORM PTO-1449 (REV. 7-80) | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | | | | | ATTY. DOCKET NO.: 200.1133 | SERIAL NO.: 09781,081 10/700,906 | | | | |
| LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary) | | | | | | | | APPLICANT(S): Oshlack, et al. | | | | | |
| | | | | | | | | FILING DATE: February 8, 2001 11/04/03 | | GROUP: 1615 | | | |
| U.S. PATENT DOCUMENTS | | | | | | | | | | | | | |
| *EXAMINER INITIAL | | DOCUMENT NUMBER | | | | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE | | | |
| HS | BA | 4 | 8 | 4 | 4 | 9 | 1 | 0 | 07/04/1989 | Leslie, et al. | 424 | 494 | |
| FOREIGN PATENT DOCUMENTS | | | | | | | | | | TRANSLATION | | | |
| | | DOCUMENT NUMBER | | | | DATE | COUNTRY | CLASS | SUBCLASS | | YES | NO | |
| | BB | | | | | | | | | | | | |
| OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | | | | | | | | | |
| HS | BC | Archer, Sydney; "Historical Perspective on the Chemistry and Development of Naltrexone"; Naltrexone: Research Monograph 28 (1980) pg. 3-9 | | | | | | | | | | | |
| | BD | Baum, et al., "The Impact of the Addition of Naloxone on the Use and Abuse of Pentazocine"; Public Health Reports (1987) Vol. 102, No. 4 pg. 426-429 | | | | | | | | | | | |
| | BE | Rapaka, et al., "Discovery of Novel Opioid Medications"; NIDA Research Monograph 147 (1995) pg. 53-83 | | | | | | | | | | | |
| | BF | Bloom, et al., "Clinical Studies with Naloxone/Methadone in a Ratio of 1:20"; 5 th National Conference on Methadone Treatment (1973) Vol 2, pg. 1342 - 1349 | | | | | | | | | | | |
| | BG | Blachly, M.D., "Naloxone in Opiate Addiction"; Current Psychiatric Therapies (1976) pg. 209-213 | | | | | | | | | | | |
| | BH | Briscoe, et al., "Methocloccinamox: Time Course of Changes in Alfentanil-Reinforced Responding in Rhesus Monkeys"; Psychopharmacology (2000) 148: pg. 393-399 | | | | | | | | | | | |
| | BI | Abstract of Bromm, et al., "A Sensitive Method to Evaluate Effects of Analgesics in Man"; Meth and Find Exptl Clin Pharmacol 5 (8) (1983) pg. 545-551 | | | | | | | | | | | |
| | BJ | Bullingham, et al., "Clinical Pharmacokinetics of Narcotic Agonist-Antagonist Drugs"; Clinical Pharm. (1983) 8: 332-343 | | | | | | | | | | | |
| | BK | Calimlim, et al., "Effect of Naloxone on the Analgesic Activity of Methadone in a 1:10 Oral Combination"; Clin Pharmacol and Ther (1974) Vol. 15; No. 6 pg. 556-564 | | | | | | | | | | | |
| | BL | Caruso, et al., "Methadone and Naloxone in Combination (Naldone®) for the Treatment of Heroin Addicts"; Bristol Laboratories, pg. 1336-1341F (1973) | | | | | | | | | | | |
| | BM | Cherny, Nathan I., "Opioid Analgesics"; Drugs (1996) May: 51 (5) pg. 713-737 | | | | | | | | | | | |
| | BN | Chiang, et al., "Clinical Evaluation of a Naltrexone Sustained-Release Preparation"; Drug and Alcohol Dependence (1985) 16, pg. 1-8 | | | | | | | | | | | |
| | BO | Chiang, et al., "Kinetics of a Naltrexone Sustained-Release Preparation"; Clin. Pharmacol Ther (1984) Vol. 36, No. 5, pg. 704-708 | | | | | | | | | | | |
| ↓ | BP | Comer, et al., "Depot Naltrexone: Long-lasting Antagonism of the effects of heroin in humans"; Psychopharmacology (2002) 159; pg. 351-360 | | | | | | | | | | | |
| HS | BQ | Crabtree, et al., "Review of Naltrexone, a long-acting opiate antagonist"; Clinical Pharmacy, Vol 3 (1984) pg. 273-280 | | | | | | | | | | | |
| EXAMINER | | /Humera Sheikh/ | | | | DATE CONSIDERED | | 01/21/2007 | | | | | |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | | | | | | | | | |

| FORM PTO-1449 (REV. 7-80) | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | | | | | ATTY. DOCKET NO.: 200.1133 | SERIAL NO.: 09/761,981 <i>10/20/906</i> | | | | |
|---|----|--|---|---|---|---|---|---|--|------------------|----------|----------------------------|----|
| LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary) | | | | | | | | APPLICANT(S): Oshlack, et al. | | | | | |
| | | | | | | | | FILING DATE: February 6, 2001- <i>11/04/03</i> | GROUP: 1615 | | | | |
| U.S. PATENT DOCUMENTS | | | | | | | | | | | | | |
| *EXAMINER INITIAL | | DOCUMENT NUMBER | | | | | | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE | |
| HS | CA | 4 | 8 | 6 | 7 | 9 | 8 | 5 | 09/19/1989 | Heafield, et al. | 424 | 461 | |
| FOREIGN PATENT DOCUMENTS | | | | | | | | | | TRANSLATION | | | |
| | | DOCUMENT NUMBER | | | | | | DATE | COUNTRY | CLASS | SUBCLASS | YES | NO |
| | CB | | | | | | | | | | | | |
| OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | | | | | | | | | |
| HS | CC | Crain et al., "Antagonists of excitatory opioid receptor functions enhance morphine's analgesic potency and attenuate opioid tolerance/dependence liability"; Dept. Of Neuroscience, Albert Einstein College of Medicine, Pain 82 (1999) pg. 1-11 | | | | | | | | | | | |
| | CD | Crain et al., "Antagonists of excitatory opioid receptor functions enhance morphine's analgesic potency and attenuate opioid tolerance/dependence liability"; Dept. Of Neuroscience, Albert Einstein College of Medicine, Pain 84 (2000) pg. 121-131 | | | | | | | | | | | |
| | CE | Fink, et al., "Naloxone in Heroin Dependence"; Clin Pharm and Therapeutics, Vol 9, No. 5; pg. 568-577 (1968) | | | | | | | | | | | |
| | CF | Fishman, et al., "Disposition of Naloxone-7,8- ³ H in Normal & Narcotic-Dependent Men"; J. of Pharm. and Experimental Therapeutics (1973) Vol 187, No. 3, pg. 575-580 | | | | | | | | | | | |
| | CG | Fraser, Albert D., et al., "Clinical Toxicology of Drugs Used in the Treatment of Opiate Dependency"; Clinical Toxicology 1, (1990) Vol 10, No. 2, pg. 375-386 | | | | | | | | | | | |
| | CH | Freye, et al., "Effects of Tramadol and Tilidine/Naloxone on Oral-Caecal Transit & Pupillary Light Reflex"; Arzneim.-Forsch/Drug Res. 50 (1) (2000) pg. 24-30 | | | | | | | | | | | |
| | CI | Fudala, et al., "Effects of Butenorphine and Naloxone in Morphine-Stabilized Opioid Addicts"; Drug and Alcohol Dependence 50 (1998) pg. 1-8 | | | | | | | | | | | |
| | CJ | Fudala, et al., "Human Pharmacology and Abuse Potential of Nalmefene"; Clin Pharm and Thera (1991) Vol 49, 3, pg. 300-306 | | | | | | | | | | | |
| | CK | Gal, et al., "Prolonged Blockade of Opioid Effect with Oral Nalmefene"; Clin Pharmacol Ther. (1986) pg. 537-542 | | | | | | | | | | | |
| | CL | Gerra, et al., "Clonidine and Opiate Receptor Antagonists in the Treatment of Heroin Addiction"; J. Substance Abuse Treatment (1995) Vol 12, 1, pg. 35-41 | | | | | | | | | | | |
| | CM | Ghodse, et al., "Opioid analgesics and narcotic antagonists"; Side Effects of Drugs (2000) Annual 23, Ch. 8, pg. 96-113 | | | | | | | | | | | |
| | CN | Glatt, William, M.D. FACP, "A New Method for Detoxifying Opioid-Dependent Patients"; J. Substance Abuse Treatment (1999) Vol 17, No 3, pg. 193-197 | | | | | | | | | | | |
| HS | CP | Gold, et al., "Rapid Opioid Detoxification during General Anesthesia"; Anesthesiology (1999) Vol 91, No 6, 1639-1647 | | | | | | | | | | | |
| EXAMINER <i>/Humera Sheikh/</i> | | | | | | | | DATE CONSIDERED <i>01/21/2007</i> | | | | | |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | | | | | | | | | |

| | | | | | | | | | | | | | |
|---|----|--|---|---|---|---|---|-------------------------------|-------------------------------|---------------------------|------------|----------------------------|----|
| FORM PTO-1449 (REV. 7-80) | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | | | | | | ATTY. DOCKET NO.: 200.1133 | SERIAL NO.: 097761,087 | 10/700,906 | | |
| LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary) | | APPLICANT(S): Oshlack, et al. | | | | | | | | | | | |
| | | FILING DATE: February 8, 2001 | | | | | | | GROUP: 1615 | | | | |
| U.S. PATENT DOCUMENTS | | | | | | | | | | | | | |
| *EXAMINER INITIAL | | DOCUMENT NUMBER | | | | | | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE | |
| HS | DA | 4 | 9 | 4 | 0 | 5 | 8 | 7 | 07/10/1990 | Jenkins, et al. | 424 | 480 | |
| FOREIGN PATENT DOCUMENTS | | | | | | | | | | | | | |
| | | DOCUMENT NUMBER | | | | | | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
| | | DB | | | | | | | | | | YES | NO |
| OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | | | | | | | | | |
| HS | DC | Gupta, et al., "Morphine Combined with Doxapram or Naloxone"; Anaesthesia (1974) Vol 29 pg. 33-39 | | | | | | | | | | | |
| | DD | Richter, et al., "Clinical Investigation on the Development of Dependence during Oral Therapy with Tramadol"; Arzneim-Forsch/Drug Res. 35 (No 11) (1985) pg. 1742-1744 | | | | | | | | | | | |
| | DE | Rosen, et al., "Effect of Clonidine Pretreatment on Naloxone-Precipitated Opiate Withdrawal"; J. of Pharm. and Experimental Ther. (1996) Vol 276, No 3, pg. 1128-1135 | | | | | | | | | | | |
| | DF | Rosen, et al., "The effect of lamotrigine on naloxone-precipitated opiate withdrawal"; Drug and Alcohol Dependence (1998) Vol 52, pg. 173-176 | | | | | | | | | | | |
| | DG | Rosen, et al., "A pilot study of dextromethorphan in naloxone-precipitated opiate withdrawal"; European J. of Pharm. (1996) Vol 307, pg. 251-257 | | | | | | | | | | | |
| | DH | Schuh, et al., "Buprenorphine, Morphine and Naloxone Effects during Ascending Morphine Maintenance in Humans"; J. of Pharm. and Experimental Ther. (1996) Vol 278, 2, pg. 836-846 | | | | | | | | | | | |
| | DI | Schuh, et al., "Onset, magnitude and duration of opioid blockade produced by buprenorphine and naltrexone in humans"; Psychopharmacology (1999) Vol 145, pg. 162-174 | | | | | | | | | | | |
| | DJ | Stevens, et al., "Nonspecific Excitatory Effects of Morphine: Reverse-Order Precipitated Withdrawal and Dose-Dose Interactions"; Psychopharmacology (1981) Vol 75, pg. 210-211 | | | | | | | | | | | |
| | DK | Stine, et al., "Reduction of Opiate Withdrawal-like Symptoms by Cocaine Abuse during Methadone and Buprenorphine Maintenance"; Am. J. Drug Alcohol Abuse (1994) Vol 20, (4), pg. 445-458 | | | | | | | | | | | |
| | DL | Stine, et al., "Use of Drug Combinations in Treatment of Opioid Withdrawal"; J. of Clinical Psych. (1992) Vol 12, No. 3, pg. 203-209 | | | | | | | | | | | |
| | DM | Stoller, et al., "Effects of buprenorphine/naloxone in opioid-dependent humans"; Psychopharmacology (2001) Vol 154, pg. 230-242 | | | | | | | | | | | |
| | DN | Strain, et al., "Acute effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers"; J. of Pharm. and Experimental Ther. (1992) Vol 261, No. 3, pg. 985-993 | | | | | | | | | | | |
| | DO | Strain, et al., "Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers"; Psychopharmacology (2000) Vol 148, pg. 374-383 | | | | | | | | | | | |
| | DP | Strain, et al., "Precipitated Withdrawal by Pentazocine in Methadone-Maintained Volunteers"; J. of Pharm. and Experimental Ther. (1993) Vol 267, No 2, pg. 624-634 | | | | | | | | | | | |
| | DQ | Tai, et al., "Naltrexone: An Antagonist Therapy for Heroin Addiction"; NIDA (1997) 5 pages | | | | | | | | | | | |
| HS | DR | Umbrecht, et al., "Naltrexone shortened opioid detoxification with buprenorphine"; Drug and Alcohol Dependence (1999) Vol 56, pg. 181-190 | | | | | | | | | | | |
| EXAMINER <i>/Humera Sheikh/</i> | | | | | | | | DATE CONSIDERED 01/21/2007 | | | | | |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | | | | | | | | | |

| | | | | | | | | | | | | | |
|--|----|--|---|---|---|-----------------------------------|----------------------------------|---------------------------|----------------|----------------------------|-----|-----|--|
| FORM PTO-1449 (REV. 7-80) | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | | | | ATTY. DOCKET NO.: 200.1133 | SERIAL NO.: 09/781,081 | 10/700,906 | | | | |
| LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary) | | | | | | | APPLICANT(S): Oshlack, et al. | | | | | | |
| | | | | | | | FILING DATE: February 8, 2001 | 11/04/03 | GROUP: 1615 | | | | |
| U.S. PATENT DOCUMENTS | | | | | | | | | | | | | |
| *EXAMINER INITIAL | | DOCUMENT NUMBER | | | | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE | | | |
| HS | EA | 4 | 9 | 7 | 0 | 0 | 7 | 5 | 11/13/1990 | Oshlack | 424 | 451 | |
| FOREIGN PATENT DOCUMENTS | | | | | | | | | | | | | |
| | | DOCUMENT NUMBER | | | | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | | | |
| | | EB | | | | | | | | YES | NO | | |
| OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | | | | | | | | | |
| HS | EC | Vaccarino, et al., "Endogenous Opiates: 1999"; Peptides 21 (2000) pg. 1975-2034 | | | | | | | | | | | |
| | ED | Wang, et al., "Inverse agonists and neutral antagonists at μ opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence"; J. of Neurochemistry (2001) Vol 77, pg. 1590-1600 | | | | | | | | | | | |
| | EE | Way, et al., "Responsivity to Naloxone during Morphine Dependence"; Annals New York Academy of Sciences, pg. 252-261 | | | | | | | | | | | |
| | EF | Weinberg, et al., "Sublingual absorption of selected opioid analgesics"; Clin Pharm Ther (1988) Vol 44, No 3, pg. 335-342 | | | | | | | | | | | |
| | EG | Wells, et al., "In Vivo Pharmacological Characterization of SoRJ 9409, a Nonpeptidic Opioid μ -Agonists/ δ -Antagonist that Produces Limited Antinociceptive Tolerance and Attenuates Morphine Physical Dependence"; J. Pharm and Exper. Thera. (2001) Vol 297, No 2, pg. 597-605 | | | | | | | | | | | |
| | EH | Wodak, Alex, "Drug Treatment for Opioid Dependence"; Australian Prescriber (2001) Vol 24, No 1, pg. 4-6 | | | | | | | | | | | |
| | EI | Wright, et al., "Acute physical dependence in humans; repeated naloxone-precipitated withdrawal after a single-dose of methadone"; Drug and Alcohol Dependence (1991) Vol 27, pg. 139-148 | | | | | | | | | | | |
| | EJ | Zhu, et al., "Naltrexone-precipitated morphine withdrawal in infant rat is attenuated by acute administration of NOS inhibitors but not NMDA receptor antagonists"; Psychopharmacology (2000) Vol 150, pg. 325-336 | | | | | | | | | | | |
| | EK | Han, et al., "Mucoadhesive buccal disks for novel nalbuphine prodrug controlled delivery: effect of formulation variables on drug release and mucoadhesive performance"; International J. of Pharm (1999) Vol 177, pg. 201-209 | | | | | | | | | | | |
| | EL | Handal, et al., "Naloxone"; Annals of Emergency Medicine (1983) Vol 12:7, pg. 438-445 | | | | | | | | | | | |
| | EM | Harris, et al., "Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine"; Drug and Alcohol Dependence (2000) Vol 61, pg. 85-94 | | | | | | | | | | | |
| HS | EN | Hawkes, et al., "Effect of an enteric-release formulation of naloxone on intestinal transit in volunteers taking codeine"; Aliment Pharm Ther (2001) Vol 15, pg. 625-630 | | | | | | | | | | | |
| HS | EO | Högger, et al., "Comparison of tilidine/naloxone, tramadol and bromfenac in experimental pain: a double-blind randomized crossover study in healthy human volunteers"; International J. Clin Pharm and Ther (1999) Vol 37, No 8, pg. 377-385 | | | | | | | | | | | |
| EXAMINER /Humera Sheikh/ | | | | | | DATE CONSIDERED 01/21/2007 | | | | | | | |
| <p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p> | | | | | | | | | | | | | |

| FORM PTO-1449 (REV. 7-80) | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | | | | | | ATTY. DOCKET NO.: 200.1133 | SERIAL NO.: 09/781,081 <i>10/300,906</i> | | | |
|---|----|--|---|---|---|---|---|--------------------------------------|--|---|----------|----------------------------|----|
| LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary) | | | | | | | | | APPLICANT(S): Oshlack, et al. | | | | |
| | | | | | | | | | FILING DATE: February 8, 2004 <i>11/04/03</i> | GROUP: 1615 | | | |
| U.S. PATENT DOCUMENTS | | | | | | | | | | | | | |
| EXAMINER INITIAL | | DOCUMENT NUMBER | | | | | | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE | |
| HS | FA | 4 | 9 | 8 | 7 | 1 | 3 | 6 | 01/22/1991 | Kreek, et al. | 514 | 282 | |
| HS | FB | 4 | 9 | 9 | 0 | 3 | 4 | 1 | 02/05/1991 | Goldie, et al. | 424 | 484 | |
| HS | FC | 5 | 0 | 7 | 1 | 6 | 4 | 6 | 12/10/1991 | Malkowska, et al. | 424 | 497 | |
| HS | FD | 5 | 0 | 9 | 1 | 1 | 8 | 9 | 02/25/1992 | Heafield, et al. | 424 | 457 | |
| HS | FE | 5 | 2 | 1 | 5 | 7 | 5 | 8 | 06/01/1993 | Krishnamurthy | 424 | 488 | |
| HS | FF | 5 | 2 | 2 | 6 | 3 | 3 | 1 | 07/13/1993 | Thompson, et al. | 73 | 865.9 | |
| HS | FG | 5 | 2 | 6 | 6 | 3 | 3 | 1 | 11/30/1993 | Oshlack, et al. | 424 | 468 | |
| FOREIGN PATENT DOCUMENTS | | | | | | | | | | | | | |
| | | DOCUMENT NUMBER | | | | | | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
| | | | | | | | | | | | | YES | NO |
| | FH | | | | | | | | | | | | |
| OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | | | | | | | | | |
| HS | FI | Budd, Keith, "Clinical use of Opioid Antagonists"; Bailliere's Clinical Anesthesiology (1987) Vol 1, No 4, pg. 993-1011 | | | | | | | | | | | |
| | FJ | Crain, et al., "Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/dependence during chronic cotreatment"; Proc. Natl. Acad. Sci (1995) Vol 92, pg. 10540-10544 | | | | | | | | | | | |
| | FK | Howes, et al., "The Pharmacology of TR5109, a New Narcotic Agonist/Antagonist Analgesic"; NIDA Research (1979) pg. 99-105 | | | | | | | | | | | |
| | FL | Leeling, et al., "Disposition and metabolism of codorphone in the rat, dog and man"; Drug Metabolism and Disposition (1982) Vol 10, No 6, pg. 649-653 | | | | | | | | | | | |
| | FM | Amass, et al., "Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet"; Drug and Alcohol Dependence (2000) Vol 58, pg. 143-152 | | | | | | | | | | | |
| | FN | Hussain, et al., "Buccal and oral bioavailability of naloxone and naltrexone in rats"; (1987) Vol 36, pg. 127-130 | | | | | | | | | | | |
| | FO | Jasinski, et al., "The human pharmacology and abuse potential of N-allylnoroxymorphone naloxone"; J. of Pharm and Exper Thera (1967) Vol 157, No. 2, pg. 420-426 | | | | | | | | | | | |
| | FP | Jones, et al., "Nalmefene: blockade of intravenous morphine challenge effects in opioid abusing humans"; Drug and Alcohol Dependence (2000) Vol 60, pg. 29-37 | | | | | | | | | | | |
| ↓ | FQ | Kanof, et al., "Clinical Characteristics of Naloxone-Precipitated Withdrawal in Human Opioid-Dependent Subjects"; J. of Pharm and Exper Thera (1992), Vol 260, No. 1, pg. 355-363 | | | | | | | | | | | |
| HS | FR | King, et al., "Naltrexone Biotransformation and Incidence of Subjective Side Effects: A Preliminary Study"; Alcoholism: Clin and Exp Res (1997) Vol 21, No. 5, pg. 906-909 | | | | | | | | | | | |
| EXAMINER <i>/Humera Sheikh/</i> | | | | | | | | DATE CONSIDERED <i>01/21/2007</i> | | | | | |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | | | | | | | | | |

| FORM PTO-1449 (REV. 7-80) | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | | | | | | ATTY. DOCKET NO.: 200.1133 | SERIAL NO.: 09/781,087 10/700,906 | | | |
|--|----|---|---|---|---|---|---|------|-------------------------------|--------------------------------------|----------|----------------------------|----|
| LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary) | | APPLICANT(S): Oshlack, et al. | | | | | | | | | | | |
| | | FILING DATE: February 8, 2001 11/04/03 | | | | | | | GROUP: 1615 | | | | |
| U.S. PATENT DOCUMENTS | | | | | | | | | | | | | |
| *EXAMINER INITIAL | | DOCUMENT NUMBER | | | | | | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE | |
| HS | GA | 5 | 2 | 8 | 6 | 4 | 9 | 3 | 02/15/1994 | Oshlack, et al. | 424 | 468 | |
| HS | GB | 5 | 3 | 2 | 4 | 3 | 5 | 1 | 06/28/1994 | Oshlack, et al. | 106 | 153 | |
| HS | GC | 5 | 3 | 3 | 6 | 6 | 9 | 1 | 08/09/1994 | Raffa, et al. | 514 | 629 | |
| HS | GD | 5 | 3 | 5 | 6 | 4 | 6 | 7 | 10/18/1994 | Oshlack, et al. | 106 | 153 | |
| HS | GE | 5 | 4 | 1 | 1 | 7 | 4 | 5 | 05/02/1995 | Oshlack, et al. | 424 | 456 | |
| HS | GF | 5 | 4 | 6 | 0 | 8 | 2 | 6 | 10/24/1995 | Memil, et al. | 424 | 470 | |
| HS | GG | 5 | 4 | 7 | 2 | 7 | 1 | 2 | 12/05/1995 | Oshlack, et al. | 424 | 480 | |
| FOREIGN PATENT DOCUMENTS | | | | | | | | | | | | | |
| | | DOCUMENT NUMBER | | | | | | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
| | | | | | | | | | | | | YES | NO |
| HS | GH | 8 | 7 | 0 | 1 | 2 | 8 | 2 | 03/12/1987 | WO | A61K | 31/485 | |
| HS | GI | 0 | 1 | 3 | 2 | 1 | 8 | 0 | 05/10/2001 | WO (A2) | A61K | 31/485 | |
| HS | GJ | 0 | 1 | 6 | 8 | 0 | 8 | 0 | 09/20/2001 | WO (A2) | A61K | 31/00 | |
| OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | | | | | | | | | |
| HS | GK | Kogan, et al., "Estimation of the Systemic Availability and other Pharmacokinetic Parameters of Naltrexone in Man after Acute and Chronic Oral Administration"; Res. Comm. in Chem. Path. and Pharm (1977) Vol 18, No. 1; pg. 29-34 | | | | | | | | | | | |
| HS | GL | Kosten, Thomas R., M.D., "Buprenorphine for Benzodiazepine-Abusing Heroin Addicts"; Amer J. of Psychiatry (1994) Vol 1, pg. 151 | | | | | | | | | | | |
| HS | GM | Kosten, et al., "Opioid antagonist challenges in buprenorphine maintained patients"; Drug and Alcohol Dependence (1990) Vol 25, pg. 73-78 | | | | | | | | | | | |
| HS | GN | Kurland, et al., "Naloxone and the Narcotic Abuser: A Controlled Study of Partial Blockade"; Int. J. of the Addictions (1974) Vol 9, No. 5, pg. 663-672 | | | | | | | | | | | |
| HS | GO | Lee, et al., "Nalbuphine Coadministered with Morphine Prevents Tolerance and Dependence"; Anesth Analg (1997) Vol 84, pg. 810-815 | | | | | | | | | | | |
| HS | GP | Lehmann, et al.; "Influence of Naloxone on the Postoperative Analgesic and Respiratory Effects of Buprenorphine"; Eur J. Clin. Pharm. (1988) Vol 34, 343-352 | | | | | | | | | | | |
| HS | GQ | Levine, et al., "Potentiation of Pentazocine Analgesia by Low-dose Naloxone"; J Clin Invest. (1988) Vol 82, pg. 1574 - 1577 | | | | | | | | | | | |
| EXAMINER <u>/Humera Sheikh/</u> | | DATE CONSIDERED <u>01/21/2007</u> | | | | | | | | | | | |
| <p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p> | | | | | | | | | | | | | |

| FORM PTO-1449 (REV. 7-80) | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | | | | | | ATTY. DOCKET NO.: 200.1133 | SERIAL NO.: 09781,081 10/700,906 | | | |
|--|----|--|---|---|---|---|---|-------------------------------|-------------------------------|-------------------------------------|----------|----------------------------|----|
| LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary) | | APPLICANT(S): Oshlack, et al. | | | | | | | | | | | |
| | | FILING DATE: February 8, 2001 11/04/03 | | | | | | | GROUP: 1615 | | | | |
| U.S. PATENT DOCUMENTS | | | | | | | | | | | | | |
| *EXAMINER INITIAL | | DOCUMENT NUMBER | | | | | | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE | |
| HS | HA | 5 | 4 | 7 | 8 | 5 | 7 | 7 | 12/26/1995 | Sackler, et al. | 424 | 489 | |
| HS | HB | 5 | 5 | 0 | 0 | 2 | 2 | 7 | 03/19/1996 | Oshlack, et al. | 424 | 476 | |
| HS | HC | 5 | 5 | 0 | 8 | 0 | 4 | 2 | 04/16/1996 | Oshlack, et al. | 424 | 468 | |
| HS | HD | 5 | 5 | 0 | 8 | 0 | 4 | 3 | 04/16/1996 | Krishnamurthy | 424 | 484 | |
| HS | HE | 5 | 5 | 4 | 9 | 9 | 1 | 2 | 08/27/1996 | Oshlack, et al. | 424 | 468 | |
| HS | HF | 5 | 5 | 5 | 2 | 4 | 2 | 2 | 09/03/1996 | Gauthier, et al. | 514 | 368 | |
| HS | HG | 5 | 5 | 9 | 1 | 4 | 5 | 2 | 01/07/1997 | Miller, et al. | 424 | 468 | |
| HS | HH | 5 | 6 | 0 | 1 | 8 | 4 | 5 | 02/11/1997 | Buxton, et al. | 424 | 495 | |
| HS | HI | 5 | 6 | 2 | 2 | 7 | 2 | 2 | 04/22/1997 | Knott, et al. | 424 | 494 | |
| HS | HJ | 5 | 6 | 3 | 9 | 4 | 7 | 6 | 06/17/1997 | Oshlack, et al. | 424 | 468 | |
| FOREIGN PATENT DOCUMENTS | | | | | | | | | | | | | |
| | | DOCUMENT NUMBER | | | | | | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
| | | | | | | | | | | | | YES | NO |
| | HK | | | | | | | | | | | | |
| OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | | | | | | | | | |
| HS | HL | Loimer, et al., "Combined Naloxone/Methadone Preparations for Opiate Substitution Therapy"; J. of Substance Abuse Treatment (1991) Vol 8, pg. 157-160 | | | | | | | | | | | |
| HS | HM | Martin, et al., "Bioavailability Investigation of a New Tildine/Naloxone Liquid Formulation Compared to a Reference Formulation"; Arzneim.-Forsch./Drug Res. (1999) Vol 49, pg. 599-607 | | | | | | | | | | | |
| HS | HN | Martin, et al., "Demonstration of Tolerance to and Physical Dependence on N-allylnormorphine (Nalorphine)"; J. of Pharm and Exper Thera (1965) Vol 150, No. 3, pg. 437-442 | | | | | | | | | | | |
| HS | HO | Mendelson, et al., "Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers"; Psychopharmacology (1999) Vol 141, pg. 37-46 | | | | | | | | | | | |
| HS | HP | Mendelson, et al., "Buprenorphine and Naloxone Interactions in Methadone Maintenance Patients"; Society of Biological Psychiatry (1997) Vol 41, pg. 1095-1101 | | | | | | | | | | | |
| HS | HQ | Nutt, et al., "Methadone-naloxone mixtures for use in methadone maintenance programs"; Clin Pharma and Thera, Vol 15, No. 2, pg. 156-166 | | | | | | | | | | | |
| HS | HR | Parwatikar, et al., "Methadone-naloxone in combination for the treatment of heroin addicts"; Clin Pharm and Thera, Vol 14, No. 6, pg. 941-948 (1973) | | | | | | | | | | | |
| EXAMINER <i>/Humera Sheikh/</i> | | | | | | | | DATE CONSIDERED 01/21/2007 | | | | | |
| <p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p> | | | | | | | | | | | | | |

| FORM PTO-1449 (REV. 7-80) | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | | | | | | ATTY. DOCKET NO.: 200.1133 | | SERIAL NO.: 09/781,981 <u>10/900,906</u> | | | |
|---|----|---|---|---|---|---|---|---|--|-----------------|---|----------|----------------------------|----|
| LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary) | | | | | | | | | APPLICANT(S): Oshlack, et al. | | | | | |
| | | | | | | | | | FILING DATE: <u>February 8, 2001</u> <u>1/14/03</u> | | GROUP: 1615 | | | |
| U.S. PATENT DOCUMENTS | | | | | | | | | | | | | | |
| *EXAMINER INITIAL | | DOCUMENT NUMBER | | | | | | | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE | |
| HS | IA | 5 | 6 | 5 | 6 | 2 | 9 | 5 | 08/12/1997 | Oshlack, et al. | 424 | 468 | | |
| HS | IB | 5 | 6 | 7 | 0 | 1 | 7 | 2 | 09/23/1997 | Buxton, et al. | 424 | 495 | | |
| HS | IC | 5 | 6 | 7 | 2 | 3 | 6 | 0 | 09/30/1997 | Sackler, et al. | 424 | 490 | | |
| HS | ID | 5 | 6 | 8 | 1 | 5 | 8 | 5 | 10/28/1997 | Oshlack, et al. | 424 | 494 | | |
| HS | IE | 5 | 7 | 6 | 3 | 4 | 5 | 2 | 06/09/1998 | Miller, et al. | 514 | 282 | | |
| HS | IF | 5 | 7 | 8 | 0 | 4 | 7 | 9 | 07/14/1998 | Kim | 514 | 282 | | |
| HS | IG | 5 | 8 | 1 | 1 | 1 | 2 | 6 | 09/22/1998 | Krishnamurthy | 424 | 498 | | |
| HS | IH | 5 | 8 | 3 | 4 | 4 | 7 | 7 | 11/10/1998 | Mioduszewski | 514 | 282 | | |
| HS | II | 5 | 8 | 4 | 3 | 4 | 8 | 0 | 12/01/1998 | Miller, et al. | 424 | 484 | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | | | | | | | | |
| | | DOCUMENT NUMBER | | | | | | | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
| | | | | | | | | | | | | | YES | NO |
| | IJ | | | | | | | | | | | | | |
| OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | | | | | | | | | | |
| HS | IK | Pawarikar, et al., "Naloxone-Methadone Combination for the Treatment of Opiate Dependence"; Missouri Institute of Psychiatry, pg. 1350-1354 (1973) | | | | | | | | | | | | |
| HS | IL | Pitts, et al., "Antinociceptive and Response Rate-Altering Effects of Kappa Opioid Agonists, Spiradoline, Enadoline and U69,593, Alone and in combination with Opioid Antagonists in Squirrel Monkeys"; J. Pharm and Exper Thera (1994) Vol 271, No. 3, pg. 1501-1508 | | | | | | | | | | | | |
| HS | IM | Preston, et al., "Buprenorphine and Naloxone alone and in combination in opioid-dependent humans"; Psychopharmacology (1988) Vol 94, pg. 484-490 | | | | | | | | | | | | |
| HS | IN | Preston, et al., "Differential Naltrexone Antagonism of Hydromorphone and Pentazocine Effects in Human Volunteers"; J. Pharm and Exper Thera (1993) Vol 264, No. 2, pg. 813-823 | | | | | | | | | | | | |
| HS | IO | Preston, et al., "Effects of Sublingually given naloxone in opioid-dependent human volunteers"; Drug and Alcohol Dependence (1990) Vol 25, pg. 27-34 | | | | | | | | | | | | |
| HS | IP | Bigelow, et al., "Abuse Liability Assessment of Buprenorphine-Naloxone Combinations"; Dept. of Psychiatry and Behavioral Sciences - The Johns Hopkins University School of Medicine, pg. 145-149 (2003) | | | | | | | | | | | | |
| HS | IQ | Wikler, et al., 'N-Allylnormorphine: Effects of single doses and precipitation of acute "Abstinence Syndromes" during addiction to morphine, methadone or heroin in man (post-addicts)'; N-Allylnormorphine During Narcotic Addiction (1953) pg. 8-20 | | | | | | | | | | | | |
| EXAMINER | | /Humera Sheikh/ | | | | | | | DATE CONSIDERED | | 01/21/2007 | | | |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | | | | | | | | | | |

| FORM PTO-1449 (REV. 7-80) | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | | | | | | | ATTY. DOCKET NO.: 200.1133 | SERIAL NO.: 097781,081 <u>10/700,906</u> | |
|---|-----------------|---|---|---|---|---|---|-----------------|------------|--|---|----------------------------|
| LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary) | | | | | | | | | | APPLICANT(S): Oshlack, et al. | | |
| | | | | | | | | | | FILING DATE: February 8, 2001 <u>10/04/03</u> | GROUP: 1615 | |
| U.S. PATENT DOCUMENTS | | | | | | | | | | | | |
| *EXAMINER INITIAL | | DOCUMENT NUMBER | | | | | | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
| HS | JA | 5 | 8 | 4 | 9 | 2 | 4 | 0 | 12/15/1998 | Miller, et al. | 264 | 460 |
| HS | JB | 5 | 8 | 6 | 9 | 0 | 9 | 7 | 02/09/1999 | Wong, et al. | 424 | 473 |
| HS | JC | 5 | 8 | 7 | 9 | 7 | 0 | 5 | 03/09/1999 | Heafield, et al. | 424 | 464 |
| HS | JD | 5 | 8 | 9 | 1 | 4 | 7 | 1 | 04/06/1999 | Miller, et al. | 424 | 468 |
| HS | JE | 5 | 9 | 0 | 8 | 8 | 4 | 8 | 06/01/1999 | Miller, et al. | 514 | 282 |
| HS | JF | 5 | 9 | 5 | 8 | 4 | 5 | 2 | 09/28/1999 | Oshlack, et al. | 424 | 457 |
| HS | JG | 5 | 9 | 5 | 8 | 4 | 5 | 9 | 09/28/1999 | Chasin, et al. | 424 | 490 |
| HS | JH | 5 | 9 | 6 | 5 | 1 | 6 | 1 | 10/12/1999 | Oshlack, et al. | 424 | 457 |
| HS | JI | 5 | 9 | 6 | 5 | 1 | 6 | 3 | 10/12/1999 | Miller, et al. | 424 | 468 |
| HS | JJ | 5 | 9 | 6 | 8 | 5 | 5 | 1 | 10/19/1999 | Oshlack, et al. | 424 | 456 |
| FOREIGN PATENT DOCUMENTS | | | | | | | | | | | | |
| | | DOCUMENT NUMBER | | | | | | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION |
| | | JK | | | | | | | | | | YES |
| | | | | | | | | | | | | NO |
| OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | | | | | | | | |
| HS | JL | Zaks, et al., "Naloxone Treatment of Opiate Dependence"; JAMA (1971) Vol 215, No. 13, pg. 2108-2110 | | | | | | | | | | |
| HS | JM | Barton, et al., "Intranasal Administration of Naloxone by Paramedics"; Prehospital Emergency Care (2002) Vol 6, No. 1, pg. 54-58 | | | | | | | | | | |
| HS | JN | Blachly, Paul, H., M.D., "Naloxone in Opiate Addiction"; Current Psychiatric Therapies (1976) pg. 209-213 | | | | | | | | | | |
| HS | JO | Bashaw, et al., "Relative bioavailability of controlled-release oral morphine sulfate during naltrexone blockade"; Inter J. of Clin Pharm and Thera (1995) Vol 33, No. 9, 524-529 | | | | | | | | | | |
| HS | JP | Jasinski, D.R., "Assessment of the Abuse Potentiality of Morphinelike Drugs (Methods Used in Man)"; Drug Addiction (1977) pg. 197-258 | | | | | | | | | | |
| HS | JQ | Johnson, et al., "Buprenorphine and Naloxone for Heroin Dependence"; Substance Use Disorders (2000) pg. 519-526 | | | | | | | | | | |
| HS | JR | Strain, et al., "Opioid antagonist effects of dezocine in opioid-dependent humans"; Clin Pharm and Thera (1996) Vol 60, No. 2, pg. 206-217 | | | | | | | | | | |
| EXAMINER | /Humera Sheikh/ | | | | | | | DATE CONSIDERED | 01/21/2007 | | | |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | | | | | | | | |

| FORM PTO-1449 (REV. 7-80) | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | | | | | | ATTY. DOCKET NO.: 200.1133 | SERIAL NO.: 097781,081 <i>10/700,906</i> | | | |
|--|----|--|---|---|---|---|---|-----------------------------------|---|---|----------|----------------------------|----|
| LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary) | | | | | | | | | APPLICANT(S): Oshlack, et al. | | | | |
| | | | | | | | | | FILING DATE: <i>February 8, 2001</i> | GROUP: 1615 | | | |
| U.S. PATENT DOCUMENTS | | | | | | | | | | | | | |
| *EXAMINER INITIAL | | DOCUMENT NUMBER | | | | | | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE | |
| HS | KA | 6 | 0 | 2 | 4 | 9 | 8 | 2 | 02/15/2000 | Oshlack, et al. | 424 | 476 | |
| | KB | 6 | 0 | 6 | 8 | 8 | 5 | 5 | 05/30/2000 | Leslie, et al. | 424 | 468 | |
| | KC | 6 | 0 | 7 | 7 | 5 | 3 | 2 | 06/20/2000 | Malkowska, et al. | 424 | 457 | |
| | KD | 6 | 0 | 7 | 7 | 5 | 3 | 3 | 06/20/2000 | Oshlack, et al. | 424 | 461 | |
| | KE | 6 | 1 | 0 | 3 | 2 | 5 | 8 | 08/15/2000 | Simon | 424 | 449 | |
| | KF | 6 | 1 | 0 | 3 | 2 | 6 | 1 | 08/15/2001 | Chasin, et al. | 424 | 459 | |
| | KG | 6 | 1 | 4 | 3 | 3 | 2 | 2 | 11/07/2000 | Sackler, et al. | 424 | 459 | |
| | KH | 6 | 1 | 4 | 3 | 3 | 2 | 8 | 11/07/2000 | Heafield, et al. | 424 | 489 | |
| | KJ | 6 | 1 | 6 | 2 | 4 | 6 | 7 | 12/19/2000 | Miller, et al. | 424 | 468 | |
| | KJ | 6 | 2 | 1 | 0 | 7 | 1 | 4 | 04/03/2001 | Oshlack, et al. | 424 | 476 | |
| | KK | 6 | 2 | 5 | 4 | 8 | 8 | 7 | 07/03/2001 | Miller, et al. | 424 | 468 | |
| ▼ | KL | 6 | 2 | 6 | 1 | 5 | 9 | 9 | 07/17/2001 | Oshlack, et al. | 424 | 457 | |
| HS | KM | 6 | 2 | 9 | 4 | 1 | 9 | 5 | 09/25/2001 | Oshlack, et al. | 424 | 457 | |
| FOREIGN PATENT DOCUMENTS | | | | | | | | | | | | | |
| | | DOCUMENT NUMBER | | | | | | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
| | | | | | | | | | | | | YES | NO |
| HS | KN | 0 | 1 | 3 | 7 | 7 | 8 | 5 | 05/31/2001 | WO (A2) | A61K | | |
| HS | KO | 0 | 1 | 5 | 2 | 8 | 5 | 1 | 07/26/2001 | WO (A1) | A61K | 31/485 | |
| HS | KP | 0 | 1 | 8 | 5 | 2 | 5 | 7 | 11/15/2001 | WO (A2) | A61P | | |
| HS | KQ | 0 | 1 | 9 | 3 | 8 | 5 | 2 | 12/13/2001 | WO (A2) | A61K | 31/00 | |
| OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | | | | | | | | | |
| HS | KR | Preston, et al., "Abuse liability studies of opioid agonist-antagonists in humans"; Drug and Alcohol Dependence (1991) Vol 28, pg. 49-82 | | | | | | | | | | | |
| HS | KS | Brennscheidt, et al., "Pharmacokinetics of Nortilidine and Naloxone after Administration of Tilidine/Naloxone Solution or Tilidine/Naloxone Sustained Release Tablets"; Arzneim.-Forsch/Drug Res. (2000) Vol 50, pg. 1015-1022 | | | | | | | | | | | |
| EXAMINER: <i>/Humera Sheikh/</i> | | | | | | | | DATE CONSIDERED <i>01/21/2007</i> | | | | | |
| <p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p> | | | | | | | | | | | | | |

| FORM PTO-1449 (REV. 7-80) | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | | | | | | | ATTY. DOCKET NO.: 200.1133 | SERIAL NO.: 09/781,081 <i>10/700,906</i> | | | |
|---|----|--|---|---|---|---|---|--------------------------------------|------------|--|---|----------------|----------------------------|----|
| LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary) | | | | | | | | | | APPLICANT(S): Oshlack, et al. | | | | |
| | | | | | | | | | | FILING DATE: February 8, 2001 <i>11/04/03</i> | | GROUP: 1615 | | |
| U.S. PATENT DOCUMENTS | | | | | | | | | | | | | | |
| *EXAMINER INITIAL | | DOCUMENT NUMBER | | | | | | | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE | |
| HS | LA | 6 | 3 | 0 | 6 | 4 | 3 | 8 | 10/23/2001 | Oshlack, et al. | 424 | 468 | | |
| HS | LB | 6 | 3 | 2 | 6 | 0 | 2 | 7 | 12/04/2001 | Miller, et al. | 424 | 468 | | |
| HS | LC | 6 | 3 | 3 | 5 | 0 | 3 | 3 | 01/01/2002 | Oshlack, et al. | 424 | 457 | | |
| HS | LD | 6 | 3 | 7 | 5 | 9 | 5 | 7 | 04/23/2002 | Kaiko, et al. | 424 | 400 | | |
| HS | LE | 6 | 3 | 8 | 7 | 4 | 0 | 4 | 05/14/2002 | Oshlack, et al. | 424 | 480 | | |
| HS | LF | 6 | 3 | 9 | 9 | 0 | 9 | 6 | 06/04/2002 | Miller, et al. | 424 | 464 | | |
| HS | LG | 6 | 4 | 7 | 5 | 4 | 9 | 4 | 11/05/2002 | Kaiko, et al. | 424 | 400 | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | | | | | | | | |
| | | DOCUMENT NUMBER | | | | | | | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
| | | | | | | | | | | | | | YES | NO |
| | LH | | | | | | | | | | | | | |
| | LJ | | | | | | | | | | | | | |
| | LJ | | | | | | | | | | | | | |
| | LK | | | | | | | | | | | | | |
| | LL | | | | | | | | | | | | | |
| OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | | | | | | | | | | |
| | LM | | | | | | | | | | | | | |
| | LN | | | | | | | | | | | | | |
| | LO | | | | | | | | | | | | | |
| | LP | | | | | | | | | | | | | |
| EXAMINER <i>/Humera Sheikh/</i> | | | | | | | | DATE CONSIDERED <i>01/21/2007</i> | | | | | | |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | | | | | | | | | | |

| FORM PTO-1449 (REV. 7-80) | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | | | | | | | ATTY. DOCKET NO.: 200.1133 | | SERIAL NO.: 09/781,981 10/700,900 | | |
|---|----|--|---|---|---|---|---|---|-------------------------------|-------------------------------|-------|---|-------------------------------|----|
| LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary) | | | | | | | | | | | | APPLICANT(S): Curtis Wright et al. | | |
| | | | | | | | | | | | | FILING DATE: February 8, 2001 11/04/03 | | |
| | | | | | | | | | | | | GROUP: 1615 | | |
| U.S. PATENT DOCUMENTS | | | | | | | | | | | | | | |
| *EXAMINE R INITIAL | | DOCUMENT NUMBER | | | | | | | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE | |
| HS | AA | 5 | 9 | 9 | 8 | 4 | 3 | 4 | 12/99 | Mitch et al. | 514 | 210.16 | | |
| | AB | 5 | 9 | 7 | 2 | 9 | 5 | 4 | 10/99 | Foss | 514 | 282 | | |
| | AC | 5 | 9 | 6 | 8 | 5 | 4 | 7 | 10/99 | Reder et al. | 424 | 449 | | |
| | AD | 5 | 9 | 4 | 2 | 2 | 4 | 1 | 8/99 | Chasin et al. | 424 | 426 | | |
| | AE | 5 | 8 | 8 | 0 | 1 | 3 | 2 | 3/99 | Hill | 514 | 282 | | |
| | AF | 5 | 8 | 6 | 6 | 1 | 6 | 4 | 2/99 | Kuczynski et al. | 424 | 472 | | |
| | AG | 5 | 8 | 6 | 0 | 9 | 5 | 0 | 1/99 | Demopoulos et al. | 604 | 49 | | |
| | AH | 5 | 8 | 5 | 8 | 0 | 1 | 7 | 1/99 | Demopoulos et al. | 604 | 890.1 | | |
| | AI | 5 | 7 | 6 | 7 | 1 | 2 | 5 | 6/98 | Crain et al. | 514 | 282 | | |
| ↓ | AJ | 5 | 6 | 3 | 3 | 2 | 5 | 9 | 5/97 | Qin et al. | 514 | 282 | | |
| HS | AK | 5 | 6 | 2 | 4 | 9 | 3 | 2 | 4/97 | Qin et al. | 514 | 282 | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | | | | | | | | |
| | | DOCUMENT NUMBER | | | | | | | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
| | | | | | | | | | | | | | YES | NO |
| HS | AL | 19 | 6 | 5 | 1 | 5 | 5 | 1 | 6/98 | DE | A61K | 31/485 | | |
| HS | AM | 29 | 7 | 1 | 9 | 7 | 0 | 4 | 2/97 | DE | A61K | 31/485 | | |
| HS | AN | 4 | 3 | 2 | 5 | 4 | 6 | 5 | 2/95 | DE | A61K | 31/485 | X | |
| HS | AO | 2 | 2 | 2 | 2 | 0 | 3 | 9 | 11/72 | DE | A61K | 27/00 | | |
| HS | AP | 0 | 9 | 1 | 3 | 1 | 5 | 2 | 6/99 | EP | A61K | 31/485 | | |
| OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | | | | | | | | | | |
| HS | AQ | Abstract, Cancer Chemother Pharmacol (1998); 42(4):287-91. | | | | | | | | | | | | |
| HS | AR | Yuan et al., Drug and Alcohol Dependence (1998); 52:161-165. | | | | | | | | | | | | |
| HS | AS | Gan et al., "Opioid-Sparing Effects of a Low-Dose Infusion of Naloxone in Patent-Administered Morphine Sulfate," Anesthesiology (1997), 87(5):1075-1080. | | | | | | | | | | | | |
| EXAMINER /Humera Sheikh/ | | | | | | | | | DATE CONSIDERED 01/21/2007 | | | | | |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | | | | | | | | | | |

| FORM PTO-1449 (REV. 7-80) | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | | | | | | ATTY. DOCKET NO.: 200.1133 | | SERIAL NO.: 09781,004 10/700 A06 | | | |
|---|----|---|---|---|---|---|---|---|--|-------------------|-------------------------------------|----------|----------------------------|----|
| LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary) | | | | | | | | | APPLICANT(S): Curtis Wright et al. | | | | | |
| | | | | | | | | | FILING DATE: February 8, 2007 4/04/03 | | GROUP: 1615 | | | |
| U.S. PATENT DOCUMENTS | | | | | | | | | | | | | | |
| *EXAMINER INITIAL | | DOCUMENT NUMBER | | | | | | | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE | |
| HS | BA | 5 | 6 | 1 | 6 | 6 | 0 | 1 | 4/97 | Khanna et al. | 514 | 399 | | |
| | BB | 5 | 5 | 8 | 5 | 3 | 4 | 8 | 12/96 | Crain et al. | 514 | 12 | | |
| | BC | 5 | 5 | 8 | 0 | 8 | 7 | 6 | 12/96 | Crain et al. | 514 | 282 | | |
| | BD | 5 | 5 | 7 | 8 | 7 | 2 | 5 | 11/96 | Portoghesi et al. | 546 | 35 | | |
| | BE | 5 | 5 | 7 | 4 | 0 | 5 | 2 | 11/96 | Rose et al. | 514 | 343 | | |
| | BF | 5 | 5 | 5 | 6 | 8 | 3 | 8 | 9/96 | Mayer et al. | 514 | 25 | | |
| | BG | 5 | 5 | 3 | 4 | 4 | 9 | 2 | 7/96 | Aston et al. | 514 | 608 | | |
| | BH | 5 | 5 | 1 | 4 | 6 | 8 | 0 | 5/96 | Weber et al. | 514 | 249 | | |
| | BI | 5 | 5 | 1 | 2 | 5 | 7 | 8 | 4/96 | Crain et al. | 514 | 282 | | |
| ▼ | BJ | 5 | 5 | 0 | 2 | 0 | 5 | 8 | 3/96 | Mayer et al. | 514 | 289 | | |
| HS | BK | 5 | 4 | 8 | 6 | 3 | 6 | 2 | 1/96 | Kitchell et al. | 424 | 426 | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | | | | | | | | |
| | | DOCUMENT NUMBER | | | | | | | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
| | | | | | | | | | | | | | YES | NO |
| HS | BL | 0 | 6 | 4 | 7 | 4 | 4 | 8 | 4/95 | EP | A61K | 31/485 | | |
| HS | BM | 0 | 3 | 5 | 2 | 3 | 6 | 1 | 1/90 | EP | A61K | 31/485 | | |
| HS | BN | 0 | 2 | 0 | 5 | 2 | 8 | 2 | 12/86 | EP | A61K | 9/22 | | |
| HS | BO | 9 | 9 | 3 | 2 | 1 | 2 | 0 | 7/99 | WO | A61K | 31/485 | | |
| HS | BP | 9 | 8 | 3 | 5 | 6 | 7 | 9 | 8/98 | WO | A61K | 31/485 | | |
| OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | | | | | | | | | | |
| HS | BQ | Shen et al., "Ultra-Low Doses of Naltrexone or Etorphine Increase Morphine's Antinociceptive Potency and Attenuate Tolerance/Dependence in Mice," Brain Research (1997), 757:176-190. | | | | | | | | | | | | |
| HS | BR | Yuan et al., Clinical Trials and Therapeutics (1997), 61:467-475. | | | | | | | | | | | | |
| EXAMINER /Humera Sheikh/ | | | | | | | | | DATE CONSIDERED 01/21/2007 | | | | | |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | | | | | | | | | | |

| FORM PTO-1449 (REV. 7-80) | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | | | | | | ATTY. DOCKET NO.: 200.1133 | | SERIAL NO.: 09/781,081, <u>10/700,806</u> | | | |
|---|----|--|---|---|---|---|---|---|---|-------------------|--|----------|----------------------------|----|
| LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary) | | | | | | | | | APPLICANT(S): Curtis Wright et al. | | | | | |
| | | | | | | | | | FILING DATE: <u>February 8, 2001</u> <u>11/04/03</u> | | GROUP: 1615 | | | |
| U.S. PATENT DOCUMENTS | | | | | | | | | | | | | | |
| *EXAMINE R INITIAL | | DOCUMENT NUMBER | | | | | | | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE | |
| HS | CA | 5 | 4 | 7 | 2 | 9 | 4 | 3 | 12/95 | Crain et al. | 514 | 12 | | |
| | CB | 5 | 4 | 5 | 7 | 2 | 0 | 8 | 10/95 | Portoghesi et al. | 546 | 35 | | |
| | CC | 5 | 4 | 2 | 6 | 1 | 1 | 2 | 6/95 | Zagon et al. | 514 | 282 | | |
| | CD | 5 | 3 | 7 | 6 | 6 | 6 | 2 | 12/94 | Ockert | 514 | 282 | | |
| | CE | 5 | 3 | 5 | 6 | 9 | 0 | 0 | 10/94 | Bihari et al. | 514 | 282 | | |
| | CF | 5 | 3 | 5 | 2 | 6 | 8 | 3 | 10/94 | Mayer et al. | 514 | 289 | | |
| | CG | 5 | 3 | 5 | 2 | 6 | 8 | 0 | 10/94 | Portoghesi et al. | 514 | 279 | | |
| | CH | 5 | 3 | 2 | 1 | 0 | 1 | 2 | 6/94 | Mayer et al. | 514 | 25 | | |
| | CI | 5 | 3 | 1 | 7 | 0 | 2 | 2 | 5/94 | Borsodi et al. | 514 | 282 | | |
| ↓ | CJ | 5 | 3 | 1 | 6 | 7 | 5 | 9 | 5/94 | Rose et al. | 424 | 10 | | |
| HS | CK | 5 | 2 | 7 | 3 | 7 | 6 | 0 | 12/93 | Oshlack et al. | 424 | 486 | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | | | | | | | | |
| | | DOCUMENT NUMBER | | | | | | | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
| | | | | | | | | | | | | | YES | NO |
| HS | CL | 9 | 7 | 3 | 3 | 5 | 6 | 6 | 9/97 | WO | A61K | 9/20 | | |
| HS | CM | 9 | 6 | 0 | 2 | 2 | 5 | 1 | 2/96 | WO | A61K | 31/485 | | |
| HS | CN | 9 | 5 | 0 | 3 | 8 | 0 | 4 | 2/95 | WO | A61K | 31/485 | | |
| HS | CO | 9 | 4 | 0 | 6 | 4 | 2 | 6 | 3/94 | WO | A61K | 31/46 | | |
| HS | CP | 8 | 3 | 0 | 3 | 1 | 9 | 7 | 9/83 | WO | A61K | 9/22 | | |
| OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | | | | | | | | | | |
| HS | CQ | Mendelson J., et al, "Buprenorphine and Naloxone Interactions in Opiate-Dependent Volunteers," Clin. Phar. Ther. (1996), 60:105-114. | | | | | | | | | | | | |
| HS | CR | Walsh et al., "Effects of Naltrexone on Response to Intravenous Cocaine, Hydromorphone and their Combination in Humans," (1996). | | | | | | | | | | | | |
| EXAMINER /Humera Sheikh/ | | | | | | | | | DATE CONSIDERED 01/21/2007 | | | | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| FORM PTO-1449 (REV. 7-80) | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | | | | | | | ATTY. DOCKET NO.: 200.1133 | | SERIAL NO.: 09/761,981 <u>10/700,906</u> | | |
|---|----|---|-----------------|---|---|---|---|--------------------------------------|------|-------------------------------|---------------------|--|----------------------------|----|
| LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary) | | | | | | | | | | | | APPLICANT(S): Curtis Wright et al. | | |
| | | | | | | | | | | | | FILING DATE: February 8, 2004 <u>11/04/03</u> | | |
| | | | | | | | | | | | | GROUP: 1615 | | |
| U.S. PATENT DOCUMENTS | | | | | | | | | | | | | | |
| EXAMINER INITIAL | | | DOCUMENT NUMBER | | | | | | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE | |
| HS | | DA | 5 | 2 | 5 | 6 | 6 | 6 | 9 | 10/93 | Askanazi et al. | 514 | 282 | |
| | | DB | 5 | 2 | 3 | 6 | 7 | 1 | 4 | 8/93 | Lee et al. | 424 | 449 | |
| | | DC | 5 | 2 | 2 | 5 | 4 | 4 | 0 | 7/93 | London et al. | 514 | 535 | |
| | | DD | 5 | 1 | 4 | 9 | 5 | 3 | 8 | 9/92 | Granger et al. | 424 | 449 | |
| | | DE | 5 | 1 | 0 | 2 | 8 | 8 | 7 | 4/92 | Goldberg | 514 | 282 | |
| | | DF | 5 | 0 | 9 | 6 | 7 | 1 | 5 | 3/92 | Sinclair | 424 | 449 | |
| | | DG | 5 | 0 | 8 | 6 | 0 | 5 | 8 | 2/92 | Sinclair et al. | 514 | 282 | |
| | | DH | 5 | 0 | 7 | 5 | 3 | 4 | 1 | 12/91 | Mendelson et al. | 514 | 282 | |
| | | DI | 4 | 9 | 3 | 5 | 4 | 2 | 8 | 6/90 | Lewis | 514 | 282 | |
| | | DJ | 4 | 8 | 8 | 9 | 8 | 6 | 0 | 12/89 | Rzeszotarski et al. | 514 | 282 | |
| HS | | DK | 4 | 8 | 8 | 2 | 3 | 3 | 5 | 11/89 | Sinclair | 514 | 282 | |
| FOREIGN PATENT DOCUMENTS | | | | | | | | | | | | | | |
| | | | DOCUMENT NUMBER | | | | | | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
| | | | | | | | | | | | | | YES | NO |
| | | DL | | | | | | | | | | | | |
| OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | | | | | | | | | | |
| HS | DM | Chih-Cheng Chien, Neuroscience Letters 190 (1995), 137-139. | | | | | | | | | | | | |
| HS | DN | Crain et al., "Ultra-Low Concentrations of Naloxone Selectively Antagonize Excitory Effects of Morphine on Sensory Neurons, Thereby Increasing Its Antinociceptive Potency and Attenuating Tolerance/Dependence During Chronic Cotreatment," Proc. Natl. Acad. Sci. USA (1995), 92:10540-10544. | | | | | | | | | | | | |
| HS | DO | Hanson, Analgesic, Antipyretic and Anti-Inflammatory Drugs in Remington's Science and Practice of Pharmacy (1995), 2:1207. | | | | | | | | | | | | |
| HS | DP | Physician's Desk Reference 48 th Ed. (1994) Montvale, NJ, 2120-2121. | | | | | | | | | | | | |
| HS | DQ | Foss et al., J. Clin Pharmacol (1993), 33:747-751. | | | | | | | | | | | | |
| EXAMINER <u>/Humera Sheikh/</u> | | | | | | | | DATE CONSIDERED <u>01/21/2007</u> | | | | | | |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | | | | | | | | | | |

| FORM PTO-1449 (REV. 7-80) | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | | | | | | ATTY. DOCKET NO.: 200.1133 | | SERIAL NO.: 09781,081 10/700,900 | | | |
|---|----|--|---|---|---|---|---|---|-------------------------------|---|-------------------------------------|----------------|-------------------------------|----|
| LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary) | | | | | | | | | | APPLICANT(S): Curtis Wright et al. | | | | |
| | | | | | | | | | | FILING DATE: February 8, 2001 11/04/03 | | GROUP: 1615 | | |
| U.S. PATENT DOCUMENTS | | | | | | | | | | | | | | |
| *EXAMINE R INITIAL | | DOCUMENT NUMBER | | | | | | | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE | |
| HS | EA | 4 | 8 | 7 | 3 | 0 | 7 | 6 | 10/89 | Fishman et al. | 412 | 10 | | |
| | EB | 4 | 8 | 6 | 1 | 7 | 8 | 1 | 8/89 | Goldberg | 514 | 282 | | |
| | EC | 4 | 8 | 6 | 1 | 5 | 9 | 8 | 8/89 | Oshlack et al. | | | | |
| | ED | 4 | 8 | 0 | 6 | 5 | 5 | 8 | 2/89 | Wuest et al. | 514 | 381 | | |
| | EE | 4 | 8 | 0 | 6 | 5 | 4 | 3 | 2/89 | Choi | 514 | 464 | | |
| | EF | 4 | 8 | 0 | 6 | 3 | 4 | 1 | 2/89 | Chien et al. | 424 | 448 | | |
| | EG | 4 | 8 | 0 | 3 | 2 | 0 | 8 | 2/89 | Pasternak | 514 | 282 | | |
| | EH | 4 | 7 | 8 | 5 | 0 | 0 | 0 | 11/88 | Kreek et al. | 514 | 282 | | |
| | EI | 4 | 7 | 6 | 9 | 3 | 7 | 2 | 9/88 | Kreek et al. | 514 | 282 | | |
| ↓ | EJ | 4 | 7 | 6 | 0 | 0 | 6 | 9 | 7/88 | Rzeszotarski et al. | 514 | 282 | | |
| HS | EK | 4 | 7 | 3 | 0 | 0 | 4 | 8 | 3/88 | Portoghesi et al. | 546 | 45 | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | | | | | | | | |
| | | DOCUMENT NUMBER | | | | | | | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
| | | | | | | | | | | | | | YES | NO |
| | EL | | | | | | | | | | | | | |
| OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | | | | | | | | | | |
| HS | EM | Holmes et al., Anesth. Analg. (1993), 77:1166-73. | | | | | | | | | | | | |
| HS | EN | Miaskowski et al., Brain Research (1992), 596:41-45. | | | | | | | | | | | | |
| HS | EO | Weinhold et al., "Buprenorphine Alone and in Combination with Naltrexone in Non-Dependent Humans," Drug and Alcohol Dependence (1992), 30:263-274. | | | | | | | | | | | | |
| HS | EP | Cappel et al., Pharma. Bioch. & Behav. (1989), 34:425-427. | | | | | | | | | | | | |
| HS | EQ | Vaccarino et al., Pain (1989), 36:103-109. | | | | | | | | | | | | |
| HS | ER | Gonzalez et al., "Naltrexone: A Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Efficacy in the Management of Opioid Dependence," Drugs (1988), 35:192-213. | | | | | | | | | | | | |
| EXAMINER /Humera Sheikh/ | | | | | | | | | | DATE CONSIDERED 01/21/2007 | | | | |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | | | | | | | | | | |

| FORM PTO-1449 (REV. 7-80) | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | | | | | | | ATTY. DOCKET NO.: 200.1133 | SERIAL NO.: 091781,081 10/700,906 | |
|---|----|---|---|---|---|---|---|-------------------------------|---------|---|--------------------------------------|----------------------------|
| LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary) | | | | | | | | | | APPLICANT(S): Curtis Wright et al. | | |
| | | | | | | | | | | FILING DATE: February 8, 2007 11/04/03 | | GROUP: 1615 |
| U.S. PATENT DOCUMENTS | | | | | | | | | | | | |
| *EXAMINE R INITIAL | | DOCUMENT NUMBER | | | | | | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
| HS | FA | 4 | 7 | 1 | 9 | 2 | 1 | 5 | 1/88 | Goldberg | 514 | 282 |
| | FB | 4 | 6 | 6 | 1 | 4 | 9 | 2 | 4/87 | Lewis et al. | 514 | 282 |
| | FC | 4 | 6 | 0 | 8 | 3 | 7 | 6 | 8/86 | Pasternak | 514 | 282 |
| | FD | 4 | 5 | 8 | 2 | 8 | 3 | 5 | 4/86 | Lewis et al. | 514 | 282 |
| | FE | 4 | 5 | 7 | 3 | 9 | 9 | 5 | 3/86 | Chen et al. | 604 | 896 |
| | FF | 4 | 4 | 6 | 4 | 3 | 7 | 8 | 8/84 | Hussain et al. | 424 | 260 |
| | FG | 4 | 4 | 5 | 7 | 9 | 3 | 3 | 7/84 | Gordon et al. | 424 | 260 |
| | FH | 4 | 4 | 5 | 1 | 4 | 7 | 0 | 5/84 | Ganti | 424 | 260 |
| | FI | 4 | 4 | 0 | 1 | 6 | 7 | 2 | 8/83 | Portoghesi et al. | 424 | 260 |
| HS | FJ | 4 | 1 | 7 | 6 | 1 | 8 | 6 | 11/79 | Goldberg | 424 | 260 |
| HS | FK | 3 | 9 | 6 | 6 | 9 | 4 | 0 | 6/76 | Pachter et al. | 424 | 260 |
| FOREIGN PATENT DOCUMENTS | | | | | | | | | | | | |
| | | DOCUMENT NUMBER | | | | | | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION |
| | FL | | | | | | | | | | | YES |
| | | | | | | | | | | | | NO |
| OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | | | | | | | | |
| HS | FM | Sunshine, et al., "Analgesic Efficacy of Pentazocine Versus a Pentazocine-Naloxone Combination Following Oral Administration," Clin. J. Pain (1988), 4:35-40. | | | | | | | | | | |
| HS | FN | Wang et al., "Crossover and Parallel Study of Oral Analgesics," J. clin. Pharmacol (1981), 21:162-168. | | | | | | | | | | |
| | FO | | | | | | | | | | | |
| | FP | | | | | | | | | | | |
| | FQ | | | | | | | | | | | |
| | FR | | | | | | | | | | | |
| EXAMINER <i>/Humera Sheikh/</i> | | | | | | | | DATE CONSIDERED 01/21/2007 | | | | |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered: Include copy of this form with next communication to applicant. | | | | | | | | | | | | |

| FORM PTO-1449 (REV. 7-80) | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | | | | | | | ATTY. DOCKET NO.: 200.1133 | | SERIAL NO.: 09/781,081-16/700,900 | | |
|---|----|--|---|---|---|---|---|---|-------|---------------------------------------|-------|--------------------------------------|----------------------------|----|
| LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary) | | | | | | | | | | APPLICANT(S): Curtis Wright et al. | | | | |
| | | | | | | | | | | FILING DATE: February 8, 2007 | | GROUP: 1615 | | |
| U.S. PATENT DOCUMENTS | | | | | | | | | | | | | | |
| *EXAMINE R INITIAL | | DOCUMENT-NUMBER | | | | | | | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE | |
| HS | GA | 3 | 8 | 7 | 9 | 5 | 5 | 5 | 4/75 | Pachter et al. | 424 | 260 | | |
| HS | GB | 3 | 7 | 7 | 3 | 9 | 5 | 5 | 11/73 | Pachter et al. | 424 | 260 | | |
| HS | GC | 3 | 6 | 7 | 6 | 5 | 5 | 7 | 7/72 | Lachman et al. | 424 | 260 | | |
| HS | GD | 3 | 4 | 9 | 3 | 6 | 5 | 7 | 2/70 | Lewenstein et al. | 424 | 260 | | |
| HS | GE | 3 | 3 | 3 | 2 | 9 | 5 | 0 | 7/67 | Blumberg et al. | 260 | 285 | | |
| HS | GF | 2 | 7 | 7 | 0 | 5 | 6 | 9 | 11/56 | Fromherz et al. | 167 | 65 | | |
| | GG | | | | | | | | | | | | | |
| | GH | | | | | | | | | | | | | |
| | GI | | | | | | | | | | | | | |
| | GJ | | | | | | | | | | | | | |
| | GK | | | | | | | | | | | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | | | | | | | | |
| | | DOCUMENT NUMBER | | | | | | | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
| | | | | | | | | | | | | | YES | NO |
| | GL | | | | | | | | | | | | | |
| OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | | | | | | | | | | |
| GM | | | | | | | | | | | | | | |
| GN | | | | | | | | | | | | | | |
| GO | | | | | | | | | | | | | | |
| GP | | | | | | | | | | | | | | |
| GQ | | | | | | | | | | | | | | |
| GR | | | | | | | | | | | | | | |
| GS | | | | | | | | | | | | | | |
| EXAMINER <u>/Humera Sheikh/</u> | | | | | | | | | | DATE CONSIDERED <u>01/21/2007</u> | | | | |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | | | | | | | | | | |

LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S): Curtis WRIGHT, et al.

FILING DATE: February 8,
2001 11/04/03

GROUP: 1615

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | | | | | | | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|------------------|----|-----------------|---|---|---|---|---|---|----------|----------------|-------|----------|----------------------------|
| HS | AA | 6 | 2 | 2 | 8 | 8 | 6 | 3 | 05/08/01 | Palermo et al. | 514 | 282 | |
| HS | AB | 6 | 2 | 7 | 7 | 3 | 8 | 4 | 08/21/01 | Kaiko et al. | 424 | 400 | |

FOREIGN PATENT DOCUMENTS

| | | DOCUMENT NUMBER | | | | | | | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION |
|----|----|-----------------|----|---|---|---|---|---|----------|---------|-------|----------|-------------|
| | | YES | NO | | | | | | | | | | |
| HS | AC | WO | 98 | 2 | 5 | 6 | 1 | 3 | 06/18/98 | EPO | A61K | 31/485 | Abstract |
| HS | AD | WO | 00 | 3 | 8 | 6 | 4 | 9 | 07/06/00 | EPO | A61K | 9/00 | Abstract |

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

| | | |
|----------|----------------------------|---|
| HS | AE | Press Release entitled "International Patent Application To Be Published on Abuse-Resistant Pain Reliever Being Developed by Purdue Pharma" August 8, 2001. |
| HS | AF | Paronis, et al., Increased Analgesic Potency of Mu Agonists after Continuous Naloxone Infusion in Rats, J Pharm. Exper. Ther. 1991 259(2) pg 582-589 |
| HS | AG | Yoburn, et al., Supersensitivity to Opioid Analgesics Following Chronic Opioid Antagonist Treatment: Relationship to Receptor Selectivity, Pharmacol. Bio. Beh. 1995 51 (2) pg 535-539 |
| HS | AH | Crain, et al., Acute thermal hyperalgesia elicited by low-dose morphine in normal mice is blocked by ultra-low-dose naltrexone, unmasking potent opioid analgesia, Brain Res. 2001 888 pg 75-82 |
| HS | AI | Zhang, et al., Down-Regulation of μ -Opioid Receptors in Rat and Monkey Dorsal Root Ganglion Neurons and Spinal Cord After Peripheral Axotomy, Neuroscience 1998 82, pg 223-240 |
| HS | AJ | Abdulla, et al., Axotomy reduces the effect of analgesic opioids yet increases the effect of nociceptin on dorsal root ganglion neurons, J. Neuro Sci 1998 18, pg 9685-9694 |
| HS | AK | Di Giannuario, et al., Orphanin FQ reduces morphine-induced dopamine release in the nucleus accumbens: a microdialysis study in rats, Neurosci. Lett. 1999 272, pg 183-186 |
| HS | AL | Cicciocioppo, et al., Effect of nociceptin/orphanin FQ on the rewarding properties of morphine, Eur. J. Pharmacol. 2000 404, pg 153-159 |
| | AM | |
| | AN | |
| EXAMINER | /Humera Sheikh/ 01/21/2007 | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to applicant.

| | | | | | | | | |
|--|----|--|--|-------------------------------|----------------------------|----------|---|----|
| FORM PTO-1449 (REV. 7-80) | | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | ATTY. DOCKET NO.: 200.1133 | | SERIAL NO.: 09/781,981 <i>10/700,906</i> | |
| LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary) | | | APPLICANT(S): Curtis WRIGHT, et al. | | | | | |
| | | | FILING DATE: February 8, 2001 <i>11/04/05</i> | | GROUP: 1615 | | | |
| U.S. PATENT DOCUMENTS | | | | | | | | |
| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE | |
| FOREIGN PATENT DOCUMENTS | | | | | | | | |
| | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
| | | | | | | | YES | NO |
| OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | | | | |
| HS | AA | Benfey, Function of Myocardial α -ADRENOCEPTORS: Life Sciences (1982) Vol. 31 pg 101-112 | | | | | | |
| HS | AB | Levine, et al., Potentiation of Pentazocine Analgesia by Low-dose Naloxone: J. Clin. Invest. (1988) Vol. 82 pg. 1574-1577 | | | | | | |
| HS | AC | Yoburn, et al., Opioid Antagonist-induced Receptor Upregulation: Effects of Concurrent Agonist Administration, (1994) (Publication Date): Brain Research Bulletin, Vol. 33 pg 237-240 | | | | | | |
| HS | AD | Bunzow, et al., Molecular cloning and tissue distribution of a putative member of the rat opioid receptor gene family that is not a μ , δ or κ opioid receptor type: FEBS Letters 347 (1994) pg. 284-288 | | | | | | |
| HS | AE | Mollereau, et al., ORL1, a novel member of the opioid receptor family: Cloning, functional expression and localization: FEBS Letters 341 (1994) pg. 33-38 | | | | | | |
| HS | AF | Wang, et al., cDNA cloning of an orphan opiate receptor gene family member and its splice variant: FEBS Letters 348 (1994) 75-79 | | | | | | |
| HS | AG | Suzuki, et al., Morphine conditioned place preference after chronic treatment with naloxone in the rat: Research Communications in Substances of Abuse. (1991) Vol. 12, No. 3 pg. 119-131 | | | | | | |
| EXAMINER <i>/Humera Sheikh/</i> | | | | DATE CONSIDERED 01/21/2007 | | | | |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | | | | |

| FORM PTO-1449 (REV. 7-80) | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | | | | | | | ATTY. DOCKET NO.: 200.1133CONS | SERIAL NO.: 10/700,906 | | |
|---|----|--|---|---|---|---|---|---|-----------------------------------|-----------------------------------|---------------------------|----------|----------------------------|
| LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary) | | APPLICANT(S): Benjamin OSHLACK et al. | | | | | | | | FILING DATE: November 4, 2003 | | | |
| | | GROUP: To be assigned <u>1615</u> | | | | | | | | | | | |
| U.S. PATENT DOCUMENTS | | | | | | | | | | | | | |
| *EXAMINER INITIAL | | DOCUMENT NUMBER | | | | | | | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
| HS | AA | 4 | 5 | 8 | 7 | 1 | 1 | 8 | 05/06/1986 | Hsiao | 424 | 459 | |
| | AB | | | | | | | | | | | | |
| | AC | | | | | | | | | | | | |
| | AD | | | | | | | | | | | | |
| | AE | | | | | | | | | | | | |
| | AF | | | | | | | | | | | | |
| | AG | | | | | | | | | | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | | | | | | | |
| | | DOCUMENT NUMBER | | | | | | | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION |
| | | | | | | | | | | | | | YES |
| | | | | | | | | | | | | | NO |
| HS | AH | 04 | 0 | 5 | 2 | 3 | 4 | 6 | 06/24/04 | WO (A1) | A61K | 9/62 | |
| HS | AI | 0 | 5 | 4 | 8 | 4 | 4 | 8 | 09/06/2000 | EP (B1) | A61K | 9/50 | abstract |
| | AJ | | | | | | | | | | | | |
| | AK | | | | | | | | | | | | |
| | AL | | | | | | | | | | | | |
| OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | | | | | | | | | |
| | AM | | | | | | | | | | | | |
| | AN | | | | | | | | | | | | |
| | AO | | | | | | | | | | | | |
| | AP | | | | | | | | | | | | |
| | AQ | | | | | | | | | | | | |
| | AR | | | | | | | | | | | | |
| | AS | | | | | | | | | | | | |
| EXAMINER <u>/Humera Sheikh/</u> | | | | | | | | | DATE CONSIDERED <u>01/21/2007</u> | | | | |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | | | | | | | | | |



Sheet 1 of 1

| FORM PTO-1449 (REV. 7-80) | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | | | | | | | ATTY. DOCKET NO.: 200.1133CONS | | SERIAL NO.: 10/700,906 | | |
|---|----|--|---|---|---|---|---|-------------------------------|------------|--|--------|---------------------------|----------------------------|----|
| LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary) | | | | | | | | | | APPLICANT(S): Benjamin OSHLACK et al. | | | | |
| | | | | | | | | | | FILING DATE: November 4, 2003 | | GROUP: 1615 | | |
| U.S. PATENT DOCUMENTS | | | | | | | | | | | | | | |
| *EXAMINER INITIAL | | DOCUMENT NUMBER | | | | | | | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE | |
| | AA | | | | | | | | | | | | | |
| | AB | | | | | | | | | | | | | |
| | AC | | | | | | | | | | | | | |
| | AD | | | | | | | | | | | | | |
| | AE | | | | | | | | | | | | | |
| | AF | | | | | | | | | | | | | |
| | AG | | | | | | | | | | | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | | | | | | | | |
| | | DOCUMENT NUMBER | | | | | | | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
| | | | | | | | | | | | | | YES | NO |
| HS | AH | 1 | 3 | 9 | 0 | 7 | 7 | 2 | 04/16/1975 | GB | A61K31 | 485 | | |
| | AI | | | | | | | | | | | | | |
| | AJ | | | | | | | | | | | | | |
| | AK | | | | | | | | | | | | | |
| | AL | | | | | | | | | | | | | |
| OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | | | | | | | | | | |
| | AM | | | | | | | | | | | | | |
| | AN | | | | | | | | | | | | | |
| | AO | | | | | | | | | | | | | |
| | AP | | | | | | | | | | | | | |
| | AQ | | | | | | | | | | | | | |
| | AR | | | | | | | | | | | | | |
| | AS | | | | | | | | | | | | | |
| EXAMINER <i>/Humera Sheikh/</i> | | | | | | | | DATE CONSIDERED 01/21/2007 | | | | | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.